Investigational Drug Information for Reparixin
✉ Email this page to a colleague
What is the development status for investigational drug Reparixin?
Reparixin is an investigational drug.
There have been 12 clinical trials for Reparixin.
The most recent clinical trial was a Phase 3 trial, which was initiated on February 14th 2021.
The most common disease conditions in clinical trials are Breast Neoplasms, Pneumonia, and COVID-19. The leading clinical trial sponsors are Dompé Farmaceutici S.p.A, PRA Health Sciences, and [disabled in preview].
There are ninety-one US patents protecting this investigational drug and nine hundred and thirty-nine international patents.
Summary for Reparixin
| US Patents | 91 |
| International Patents | 939 |
| US Patent Applications | 265 |
| WIPO Patent Applications | 182 |
| Japanese Patent Applications | 79 |
| Clinical Trial Progress | Phase 3 (2021-02-14) |
| Vendors | 37 |
Recent Clinical Trials for Reparixin
| Title | Sponsor | Phase |
|---|---|---|
| Reparixin as add-on Therapy to Standard of Care to Limit Disease Progression in Adult Patients With COVID-19. | Dompé Farmaceutici S.p.A | Phase 3 |
| To Assess Efficacy and Safety of Oral Reparixin in Patients With Fatigue and Locally Advanced / Metastatic Breast Cancer | Dompé Farmaceutici S.p.A | Phase 2 |
| Study on Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients With Severe COVID-19 Pneumonia. | Dompé Farmaceutici S.p.A | Phase 3 |
Clinical Trial Summary for Reparixin
Top disease conditions for Reparixin
Top clinical trial sponsors for Reparixin
US Patents for Reparixin
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Reparixin | See Plans and Pricing | Heterocyclic compound | Takeda Pharmaceutical Company Limited (Osaka, JP) | See Plans and Pricing |
| Reparixin | See Plans and Pricing | Heterocyclic compound | Takeda Pharmaceutical Company Limited (Osaka, JP) | See Plans and Pricing |
| Reparixin | See Plans and Pricing | Combination therapy | DIMERIX BIOSCIENCE PTY LTD. (Victoria, AU) | See Plans and Pricing |
| Reparixin | See Plans and Pricing | Heterocyclic compound | Takeda Pharmaceutical Company Limited (Osaka, JP) | See Plans and Pricing |
| Reparixin | See Plans and Pricing | Controlled-release otic structure modulating and innate immune system modulating compositions and methods for the treatment of otic disorders | OTONOMY, INC. (San Diego, CA) THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Oakland, CA) | See Plans and Pricing |
| Reparixin | See Plans and Pricing | Heterocyclic compounds and their use as retinoid-related orphan receptor (ROR) gamma-T inhibitors | Takeda Pharmaceutical Company Limited (Osaka, JP) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Reparixin
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Reparixin | Canada | CA2961033 | 2034-09-11 | See Plans and Pricing |
| Reparixin | European Patent Office | EP3192791 | 2034-09-11 | See Plans and Pricing |
| Reparixin | Japan | JPWO2016039408 | 2034-09-11 | See Plans and Pricing |
| Reparixin | World Intellectual Property Organization (WIPO) | WO2016039408 | 2034-09-11 | See Plans and Pricing |
| Reparixin | Argentina | AR098909 | 2033-07-03 | See Plans and Pricing |
| Reparixin | European Patent Office | EP3018126 | 2033-07-03 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
